Association of Platelet Serotonin Levels in Alzheimers Disease with Clinical and Cerebrospinal Fluid Markers
2016 (English)In: Journal of Alzheimer's Disease, ISSN 1387-2877, E-ISSN 1875-8908, Vol. 53, no 2, 621-630 p.Article in journal (Refereed) Published
Introduction: Serotonin (5-HT) is involved in the pathology of Alzheimers disease (AD). Objective: We aimed to measure 5-HT level in platelets in AD and explore its association with cerebrospinal fluid (CSF), AD biomarkers (amyloid-beta 1-42 (A beta(42)), total tau (t-tau), and phosphorylated tau (p-tau)), and clinical symptoms. Methods: 15 patients with AD and 20 patients with subjective cognitive impairment (SCI) were included. 5-HT metabolites were measured, in a specific fraction, using high performance liquid chromatography with electrochemical detection (HPLC-ECD). Results: Significantly lower 5-HT concentrations were observed in AD patients compared to SCI patients both after normalization against total protein (p = 0.008) or platelet count (p = 0.019). SCI patients with lower 5-HT level have higher AD CSF biomarkers, total tau (p = 0.026) and tau/A beta(42) ratio (p = 0.001), compared to those with high 5-HT levels. Conclusion: AD patients have reduced platelet 5-HT levels. In SCI, lower 5-HT content was associated with a higher AD-CSF biomarker burden.
Place, publisher, year, edition, pages
IOS PRESS , 2016. Vol. 53, no 2, 621-630 p.
Alzheimers disease; amyloid; cognition; platelet; serotonin
IdentifiersURN: urn:nbn:se:liu:diva-131591DOI: 10.3233/JAD-160022ISI: 000381207500019PubMedID: 27163811OAI: oai:DiVA.org:liu-131591DiVA: diva2:974628
Funding Agencies|Konung Gustaf V och Drottning Victorias Stiftelse; Hultmans Stiftelse2016-09-272016-09-272016-09-27